Global Equitable AI Healthcare: Grant Initiatives and Innovations

By Crystal Lubbe

October 24, 2024

The South African Medical Research Council (SAMRC) site discusses the significant initiative “Grand Challenges: Catalysing Equitable AI Use for Improved Global Health.” Overall, this program focuses on leveraging artificial intelligence (AI) to enhance healthcare systems worldwide.

Funding and Grants for Equitable AI

The Grand Challenges (GC) Network, including partners, Bill & Melinda Gates Foundation and Grand Challenges from Africa, Brazil, Ethiopia, India, and Senegal, has announced grants to support over 50 researchers and innovators. Notably, these grants form part of the initiative addressing global health challenges with Equitable AI Healthcare solutions.

Focus Areas of Equitable AI Healthcare

Funded projects under the Grand Challenges program focus on several critical healthcare areas, including:

  • Clinical Decision Support
  • Population Health & Policymaking
  • Support for Frontline Health Workers
  • Health Communications & Patient Journeys
  • Health Systems Strengthening
  • Clinical trials
  • Diagnostics
  • Population health.

Equitable AI Use

The initiative stresses the importance of an equitable approach to AI use, particularly in low- and middle-income countries (LMICs). Moreover, it seeks to ensure that the benefits of AI are relevant, affordable, and accessible, especially in communities where global health challenges are most pressing. By promoting equitable AI use, the program aims to enhance health outcomes for underserved populations.

Global Collaboration

This program is the product of collaborative efforts among various partners, including the SAMRC, the Bill & Melinda Gates Foundation, and other Grand Challenges supporters. Therefore, this cooperation emphasises the significance of local innovation paired with global backing to develop effective AI solutions tailored to specific regions.

Impact and Vision

The initiative accordingly hopes to transform healthcare delivery and improve countless lives globally. It aligns with the GC Network’s overarching vision of fostering local, regional, and global innovation ecosystems that address health and development issues with an emphasis on equitable AI use.

Funding Scale

The GC Network has invested greatly in innovative solutions, with over $1.6 billion awarded in 3,800 grants across 118 countries. The ongoing funding call reflects the commitment of the Grand Challenges initiative to support health and development innovation.

Quotes and Endorsements

Professor Ntobeko Ntusi (SAMRC) and Trevor Mundel (Gates Foundation), have expressed their robust support for the initiative. Furthermore, they emphasise the potential of equitable AI use to significantly enhance health and well-being on a global scale.

In conclusion, this initiative not only showcases a commitment to leveraging AI for global health improvement but also emphasises the importance of equity, local innovation, and collaborative efforts. With the focus on equitable AI use at its core, the Grand Challenges program stands poised to make a substantial impact in addressing urgent global health needs.

Reference url

Recent Posts

Portugal Health Spending 2025 Reaches Record €4.417 Billion Amid Rising Demand

By João L. Carapinha

May 22, 2026

Portugal health spending 2025 hit a fresh peak as the country’s publicly funded National Health Service recorded its highest annual outlay on medicines, reaching €4.417 billion according to Infarmed data. This total, already net of industry rebates and contributions, was propelled chiefly by expa...
Substandard Medicines in South Africa: Regulatory Challenges and Economic Implications

By HEOR Staff Writer

May 21, 2026

Substandard medicines in South Africa continue to infiltrate supply chains through informal markets, unlicensed outlets, and online platforms, leaving patients exposed to unregulated weight-loss injections amid stock shortages and high costs for approved options such as Ozempic. Comp...
First-in-Human Trials: Foundations and Market Implications in Health Economics
First-in-Human Trials mark the initial transition of a drug candidate from extensive preclinical research into human subjects, supplying the earliest clinical evidence on safety, pharmacokinetics, and pharmacodynamics to inform later development stages. These studies rely on a comprehensive found...